An Act To Amend Title 16 Of The Delaware Code Relating To The Healthcare Associated Infections Disclosure Act.
Impact
The amendment to the Healthcare Associated Infections Disclosure Act is significant as it enhances the state's ability to monitor and report healthcare-associated infections. By aligning with national standards, the bill aims to improve patient safety and transparency in healthcare settings. Moreover, the introduction of penalties for non-compliance, such as fines and potential termination of licensure, emphasizes the seriousness of maintaining infection control protocols. This is intended to motivate healthcare facilities to prioritize infection prevention measures.
Summary
House Bill 156 amends Title 16 of the Delaware Code, specifically relating to the Healthcare Associated Infections Disclosure Act. The primary intent of the bill is to update language and ensure consistency in terminology, particularly shifting from 'psychiatric facilities' to 'behavioral health facilities'. Additionally, it mandates adherence to the National Healthcare Safety Network (NHSN) requirements as defined by the Centers for Disease Control and Prevention (CDC). This reflects an effort to standardize healthcare reporting practices across different facilities.
Sentiment
The overall sentiment regarding HB 156 appears to be positive among its supporters, primarily from health officials and patient advocacy groups who see it as a necessary step toward protecting public health. The bill is viewed as a proactive measure that updates outdated terminology and practices in healthcare. However, some concerns have been raised about the practicality of enforcing the amendments and the potential burden on healthcare facilities to comply with heightened reporting and standards.
Contention
One notable point of contention relates to the privacy and confidentiality protections concerning healthcare-associated infection data. While the bill provides that such data should be privileged and not used against healthcare facilities in legal proceedings, there may be discussions around how this impacts accountability and transparency in healthcare. Ensuring that patient information remains confidential while also making infection rates and statistics publicly available is a complex balance that stakeholders are likely to scrutinize.
Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
Includes the definition of "primary care services" and requires that all biennial reports shall include a review and recommendation of rates for primary care services on and after September 1, 2025.
Includes the definition of "primary care services" and requires that all biennial reports shall include a review and recommendation of rates for primary care services on and after September 1, 2025.
Includes the definition of "primary care services" and requires that all biennial reports shall include a review and recommendation of rates for primary care services on and after September 1, 2025.
Provides for a two-point three percent (2.3%) increase of provider reimbursement rates for intellectual and developmental disabilities commencing October 1, 2025.